Pharmacovigilance and drug-induced rare diseases: Strengths of the French Network of Regional Pharmacovigilance Centres

Lacroix, Clémence; Mallaret, Michel; Jonville-Béra, Annie Pierre

doi:10.1016/j.therap.2020.02.012

Cited by 7 publications

(1 citation statement)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A significant portion of rare diseases manifests during childhood, with a third of afflicted children having a life expectancy not exceeding five years of age [ 77 ]. Intensifying research, coupled with the advancement of early diagnostic and therapeutic strategies for pediatric patients with rare diseases, can substantially attenuate disease progression and enhance overall quality of life.…”

Section: Discussionmentioning

confidence: 99%

Pharmacovigilance for rare diseases: a bibliometrics and knowledge-map analysis based on web of science

Xu,

Li,

et al. 2023

Orphanet J Rare Dis

View full text Add to dashboard Cite

Objectives The aims of this paper is to search and explore publications in the field of pharmacovigilance for rare diseases and to visualize general information, research hotspots, frontiers and future trends in the field using the bibliometric tool CiteSpace to provide evidence-based evidence for scholars. Methods We searched the Web of Science Core Collection (WoSCC) for studies related to pharmacovigilance for rare diseases, spanning January 1, 1997-October 25, 2022. CiteSpace software was utilized to discuss countries/regions, institutions, authors, journals, and keywords. Results After screening, a total of 599 valid publications were included in this study, with a significant upward trend in the number of publications. These studies were from 68 countries/regions with the United States and the United Kingdom making the largest contributions to the field. 4,806 research scholars from 493 institutions conducted studies on pharmacovigilance for rare diseases. Harvard University and University of California were the top two productive institutions in the research field. He Dian of the Affiliated Hospital of Guizhou Medical University and Peter G.M. Mol of the University of Groningen, The Netherlands, were the two most prolific researchers. The Cochrane Database of Systematic Reviews and the New England Journal of Medicine were the journals with the highest number of articles and co-citation frequency respectively. Clinical trial, therapy and adverse event were the top three most cited keywords. Conclusions Based on keywords co-occurrence analysis, four research topics were identified: orphan drug clinical trials, postmarketing ADR surveillance for orphan drugs, rare diseases and orphan drug management, and diagnosis and treatment of rare diseases. Immune-related adverse reactions and benefit-risk assessment of enzyme replacement therapy were at the forefront of research in this field. Treatment outcomes, early diagnosis and natural history studies of rare diseases may become hotspots for future research.

show abstract

Section: Discussionmentioning

confidence: 99%